Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Triflusal

W McNeely1, K L Goa

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|June 9, 1998
PubMed
Summary
This summary is machine-generated.

Triflusal, an antiplatelet drug, effectively reduced myocardial infarction in unstable angina and improved walking in peripheral arteriopathy. It also showed benefits in carotid stenosis and post-surgery recovery, with reduced bleeding risk compared to aspirin.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential.

CNS drugs·2016
Same author

Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

CNS drugs·2013
Same author

Optical path clearing and enhanced transmission through colloidal suspensions.

Optics express·2010
Same author

Clinical investigation of hospitalized human cases of West Nile virus infection in Houston, Texas, 2002-2004.

Vector borne and zoonotic diseases (Larchmont, N.Y.)·2008
Same author

Adjuvanted influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Liposomal influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Thrombosis Research

Background:

  • Triflusal is an antiplatelet agent structurally related to salicylates.
  • Its antiplatelet effects stem from inhibiting platelet arachidonic acid metabolism.

Purpose of the Study:

  • To evaluate triflusal's efficacy and safety in various cardiovascular conditions.
  • To compare triflusal with aspirin and placebo in clinical settings.

Main Methods:

  • Clinical trials involving patients with unstable angina, peripheral arteriopathy, atherothrombotic stroke, aortocoronary vein grafting, and hip surgery.
  • Comparison of triflusal against placebo and aspirin.

Main Results:

  • Significant reduction in nonfatal myocardial infarction in unstable angina patients.

Related Experiment Videos

  • Marked improvement in walking distances for peripheral arteriopathy patients.
  • Favorable outcomes in carotid stenosis, aortocoronary vein grafting, and reduced blood transfusion/hemorrhage risk compared to aspirin.

    • Conclusions:

    • Triflusal demonstrates significant benefits in preventing cardiovascular events and improving outcomes in specific patient groups.
    • Triflusal offers a favorable safety profile, particularly regarding bleeding risk, compared to aspirin.